Aidoc

1.1 Corporate Identity, Operating Architecture, and Dual Footprint

Aidoc operates as an enterprise clinical artificial intelligence software provider dedicated to accelerating diagnostic decision-making and mitigating diagnostic errors across acute health systems. Legally organized through Aidoc Medical Ltd. in Tel Aviv, Israel, alongside Aidoc Inc. in Manhattan, New York, the organization maintains a dual corporate operating footprint that links Israeli defense-derived deep technical engineering with commercial health system distribution in the United States and international markets. The platform centers on the proprietary CARE clinical foundation model and the aiOS enterprise AI operating system, which embeds algorithmic image triage and clinical workflow notifications directly into existing hospital Picture Archiving and Communication Systems (PACS) and Electronic Health Record (EHR) environments. In contrast to isolated point-solution algorithms that create departmental IT friction, Aidoc's architectural strategy emphasizes centralized AI orchestration, FHIR-based clinical EHR integrations with systems like Epic, and comprehensive diagnostic workflow automation spanning urgent triage notifications to generative radiology draft report creation.[CO001, CO002, CO003, CO004]

1.2 Founding Leadership, Executive Background, and Key-Person Dependency

Aidoc was co-founded in October 2015 by Chief Executive Officer Elad Walach alongside fellow alumni of the elite Talpiot technology program in the Israeli Defense Forces. Walach, who holds a BSc in Computer Science and Physics from The Hebrew University of Jerusalem and an MS in Computer Science from Tel Aviv University, previously led artificial intelligence research within the Israeli Air Force before co-founding Aidoc. Under his ten-year executive leadership, the enterprise has grown from an initial algorithmic radiology prototype to an organization with over 400 employees and a commercial footprint in nearly 2,000 hospitals globally. The company's corporate governance structure reflects significant key-person dependence on Walach's dual operational and technical background, balanced by seasoned commercial healthcare leadership across North America and Europe. Enterprise governance incorporates strict regulatory and data protection compliance, managed under the EU-U.S. Data Privacy Framework with U.S. Federal Trade Commission oversight and independent dispute resolution mechanisms via JAMS and ICDR-AAA.[CO005, CO006, CO007, CO008]

1.3 Capitalization History, Enterprise Scale, and Milestone Evolution

Aidoc's capitalization trajectory demonstrates sustained institutional backing from premier technology and growth equity investors across five primary funding rounds. Following an initial growth phase that included a $110 million venture expansion round in June 2022, the company completed a landmark $150 million Series E financing in April 2026 led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Vision Fund 2, and NVentures (NVIDIA's venture capital arm). Disclosed cumulative funding surpassed $500 million, solidifying Aidoc's balance sheet for large-scale clinical foundation model deployments. Operationally, Aidoc's platform supports clinical decision-making for approximately 60 million patients annually, having evaluated more than 120 million cumulative patient cases to date across prominent health system networks such as Sutter Health, Wellspan Health, and Mercy. However, post-money equity valuation, exact annual recurring revenue (ARR), gross margins, and net cash burn remain undisclosed private metrics, representing material diligence gaps.[CO009, CO010, CO011, CO012, CO013]

1.4 Exhibits

2.1 Market Boundary, Taxonomy, and Status-Quo Substitutes

The market for clinical artificial intelligence in acute healthcare is structurally distinct from broader healthcare enterprise software. While general healthcare AI addresses administrative functions such as patient scheduling, billing, revenue cycle management, and supply chain logistics, clinical AI operates directly on diagnostic signals—such as computed tomography (CT) and radiograph imaging—to influence patient care pathways in real time. Acute health systems historically deployed point-solution machine learning algorithms to triage acute stroke or intracranial hemorrhage. However, health system procurement and IT leadership increasingly exclude isolated algorithms due to maintenance burdens, integration complexity, and workflow fragmentation. Instead, spend is transitioning toward enterprise clinical AI operating systems that connect disparate medical devices, picture archiving and communication systems (PACS), and electronic medical records (EMR) into a unified diagnostic infrastructure. The status quo remains dominated by manual radiologist interpretation, teleradiology service contracts, and on-call specialist escalation, all of which face severe labor shortages and escalating backlogs.[CM001, CM002, CM003, CM004]

2.2 Market Sizing Lenses, Growth Drivers, and Diagnostic Demand

Sizing the addressable market for enterprise clinical AI requires evaluating acute hospital demand, diagnostic imaging procedure volumes, and diagnostic capacity constraints rather than relying on a single broad software projection. In the United States, outpatient imaging turnaround times more than doubled between 2014 and 2023, while acute hospital emergency departments experience diagnostic delays where CT turnaround times can add up to 150 minutes to patient stays. Nationally, diagnostic errors and delays contribute to at least 400,000 deaths annually, establishing urgent clinical and operational justification for automated triage and drafting tools. Enterprise clinical AI platforms currently analyze tens of millions of patient scans across thousands of acute hospitals globally, with early commercial footprints reaching approximately 2,000 acute facilities. Capital deployment into enterprise clinical AI infrastructure remains robust, evidenced by $150 million in Series E funding in 2026 and over $500 million in cumulative disclosed capital for market leaders, reflecting institutional conviction in platform consolidation over point solutions.[CM005, CM006, CM007, CM008, CM009]

2.3 Buyer Segmentation, Procurement Pathways, and Implementation Constraints

Enterprise adoption of clinical AI is governed by multi-stakeholder procurement dynamics spanning clinical specialists, radiology group leadership, hospital operational executives, and health system CIOs. Chief Information Officers and clinical engineering teams act as key gatekeepers, demanding centralized architecture such as aiOS to eliminate departmental IT silos and ensure data privacy framework compliance. Meanwhile, Chief Medical Officers and emergency medicine leadership evaluate enterprise platforms based on demonstrable impact on throughput, length of stay, and care coordination across multi-disciplinary teams such as pulmonary embolism response teams (PERT) and stroke teams. Adoption constraints remain significant: health systems must navigate international data transfer compliance under EU-U.S. Data Privacy Framework standards, mitigate automation bias and clinical liability in generative draft reporting, and manage substantial clinical change management. Contract structures typically feature enterprise annual subscriptions, but health systems encounter ongoing evidence gaps regarding exact long-term software replacement rates and net operating margins.[CM010, CM011, CM012, CM013]

2.4 Exhibits

3.1 Competitive Landscape: Direct Peers, Incumbents, and Point Solutions

The clinical artificial intelligence market in acute and diagnostic healthcare has evolved from isolated algorithmic competitions into a multi-tiered platform landscape. In acute radiological triage, three primary venture-backed platforms—Aidoc, Viz.ai, and RapidAI—dominate commercial conversations across United States hospital networks. Each of the three contenders reports approximately 2,000 hospital relationships, creating parity in top-line reach claims that obscures true account depth and multi-homing across health systems. Beyond this core trio, the broader landscape divides into incumbent enterprise imaging IT and Picture Archiving and Communication Systems (PACS) providers, specialized point-solution computer-aided triage (CADt) algorithm developers, and adjacent ambulatory health IT systems such as Practice Fusion. While ambulatory EHR systems operate in distinct outpatient charting and billing workflows without diagnostic imaging triage, incumbent PACS vendors serve as both critical integration channels and potential gatekeepers for AI worklist injection. Competitive differentiation among the direct triumvirate has largely shifted away from pure stroke detection accuracy, where algorithmic performance has broadly converged across leading vendors, toward enterprise multi-specialty platform orchestration, proprietary foundation models, and institutional electronic health record integrations.[CP001, CP005, CP006, CP008]

3.2 Peer Profiles and Platform vs. Point-Solution Architecture

Detailed analysis of peer architectures reveals divergent strategic trajectories across the clinical AI ecosystem. Aidoc has positioned itself as an enterprise AI operating system through its proprietary aiOS layer and CARE foundation model framework, designed to orchestrate both native algorithms and vetted third-party modules across radiology, cardiology, and neurology. This contrasts with Viz.ai's historic focus on mobile-first neurovascular care coordination and specialist activation, and RapidAI's foundation in advanced CT and MRI perfusion imaging analytics for stroke triage. Independent clinical evaluations indicate that point-solution CADt developers face increasing commoditization and vendor consolidation pressure, as health system Chief Information Officers increasingly refuse to manage bespoke IT integrations, server infrastructure, and vendor agreements for individual algorithmic indications. In acute settings, platform triage delivers documented operational improvements; for example, clinical data presented at the 2024 SNIS meeting highlighted a 38-minute reduction in door-to-puncture time for acute stroke patients following Aidoc's deployment. However, clinical AI performance remains highly contingent on scanner hardware protocols, slice thickness, and reconstruction kernels, necessitating site-specific validation that point-solution vendors often fail to support.[CP004, CP006, CP007, CP008, CP013]

3.3 Commercial Packaging, Deal Economics, and Budgetary Friction

Commercial procurement structures for enterprise clinical AI are characterized by multi-year SaaS commitments and significant opacity. Aidoc targets executive C-suite leadership and hospital service-line directors, closing multi-year enterprise contracts with individual deal values of $500,000 or greater, while pursuing an account expansion strategy designed to expand annual spend by at least two times while sustaining 95% retention. Unlike commodity ambulatory software where vendors like Practice Fusion publish transparent monthly per-provider pricing tiers and offer free evaluation trials, enterprise clinical AI vendors do not publish standardized rate cards. Aidoc licenses its technology through annual subscriptions structured around specific algorithm activations and annual study volume, causing total institutional software spend to escalate steeply as additional clinical indications are deployed. This pricing architecture introduces substantial procurement friction, as health systems must evaluate complex multi-algorithm bundles without pre-negotiation benchmarking data. Crucially, a persistent budgetary misalignment complicates procurement: while the life-saving and throughput benefits of automated triage accrue to clinical service lines like stroke neurology, vascular surgery, and emergency medicine, software licensing costs are typically charged against radiology or enterprise IT budgets.[CP002, CP003, CP009, CP011, CP012]

3.4 Moat Durability, CADt Constraints, and Alert Fatigue Risks

Evaluating the durability of Aidoc's competitive moat requires examining regulatory boundaries, alert fatigue, and health system switching barriers. Aidoc's core commercial clearances fall under the FDA's CADt (computer-aided triage and notification) classification. By regulatory statute, CADt software is authorized solely to reorder worklists and notify specialists of suspected time-critical findings; it cannot provide definitive diagnostic interpretations or substitute for a certified radiologist read. Consequently, ROI business cases premised on reduced radiologist staffing or workload elimination fail under regulatory scrutiny, as every imaging study still demands a full physician read. Furthermore, because triage models are deliberately tuned for high sensitivity to avoid false negatives on fatal pathologies like intracranial hemorrhages or pulmonary embolisms, false-positive alerts occur routinely. In health systems that do not rigorously audit real-world positive predictive value within their local patient mix, radiologist interruptive alert fatigue can rapidly erode clinician trust within months of launch. Switching costs are protected primarily by deep PACS integrations and enterprise data processing governance under the EU-US Data Privacy Framework, rather than algorithm exclusivity. Standard commercial terms cap aggregate vendor liability to recent subscription fees and disclaim diagnostic warranties, reinforcing that clinical accountability remains entirely with hospital practitioners.[CP004, CP010, CP012, CP013, CP014]

3.5 Exhibits

4.1 Revenue Model, Pricing Mechanics, and Commercial Packaging

Aidoc monetizes its clinical artificial intelligence technology primarily through a B2B enterprise software subscription model targeting hospitals, integrated delivery networks (IDNs), and outpatient imaging centers [CI001]. The commercial architecture centers on the proprietary aiOS platform, which acts as an operating system and deployment layer embedding clinical algorithms directly into existing picture archiving and communication systems (PACS) and electronic health records (EHR) [CI002]. While specific dollar-denominated list prices and per-scan software fees are strictly treated as confidential commercial terms, hospital contract structures generally combine fixed platform access fees with tiered software licensing scaled by hospital bed volume, facility count, or algorithmic coverage across clinical service lines [CI003]. Under its standard online terms of use, Aidoc restricts aggregate liability to the total fees paid by a customer in the preceding three-month period, reflecting standard enterprise SaaS contract governance [CI004]. Nevertheless, the absence of public pricing schedules or realized revenue-per-facility benchmarks limits precise quantification of contract value distribution [CI005].

4.2 Go-to-Market Motion, Sales Cycles, and Service Delivery Economics

Aidoc's go-to-market motion involves high-touch enterprise direct sales combined with strategic clinical integrations and healthcare channel relationships [CI006]. Because clinical deployment touches emergency medicine, radiology, cardiology, and neurovascular workflows, enterprise sales cycles in health systems routinely span nine to eighteen months due to institutional IT governance, HIPAA and Data Privacy Framework compliance, and physician committee evaluations [CI007]. On the cost side, Aidoc's service delivery economics encompass compute infrastructure across cloud partners like Amazon Web Services (AWS) and NVIDIA, specialized engineering overhead for foundation model development (such as CARE), and regulatory compliance maintenance [CI008]. While Aidoc reported that contracted annual recurring revenue expanded significantly in earlier growth stages, steady-state software gross margins and cloud compute expenditures per processed study remain opaque private metrics [CI009]. Operating expenses are heavily weighted toward commercial account teams, clinical deployment specialists, and specialized machine learning research personnel [CI010].

4.3 Capital Adequacy, Financing Trajectory, and Underwriting Diligence Verdict

From a financing perspective, Aidoc maintains a well-capitalized balance sheet following its $150 million Series E round in April 2026 led by Growth Equity at Goldman Sachs Alternatives, bringing cumulative disclosed funding to over $500 million [CI011, CI012]. External secondary trackers estimate Aidoc's headcount at over 600 personnel, implying substantial monthly operating payroll commitments and computational model training overhead [CI013]. While the Series E proceeds provide multi-year runway to pursue FDA submissions and product expansion—such as the First Read radiology report drafting tool—underwriting institutional diligence is obstructed by the complete opacity surrounding net revenue retention, GAAP operating losses, and cash burn rate [CI014]. Secondary market pricing and historical capitalization records remain fragmented and lack formal verification, confirming that full credit or equity valuation underwriting requires access to private financial disclosures [CI015].

4.4 Exhibits

5.1 Clinical Workflow and Product Line Definition

Aidoc positions its technology as a clinical AI operating layer designed to alleviate acute imaging backlogs in emergency and inpatient healthcare environments. Rather than acting as an autonomous diagnostic authority, Aidoc's decision-support software analyzes medical imaging scans to flag acute abnormalities, prioritize life-threatening cases on radiologist worklists, and accelerate multidisciplinary care team coordination. The product catalog spans specialized computer-vision algorithms for acute computed tomography (CT) triage—such as intracranial hemorrhage, pulmonary embolism, and abdominal abnormalities—paired with emerging generative capabilities like First Read for chest radiographs. First Read is designed to generate preliminary drafted reporting text across more than 100 pre-specified radiological findings, though final sign-off and clinical liability remain strictly reserved for certified human radiologists.[CE001, CE002, CE003, CE004]

5.2 Operating Model, Cloud Infrastructure, and Deployment Topology

Aidoc's operating architecture couples scalable cloud-based model training and inference pipelines with localized health-system interfaces. Model training and high-throughput inference routines execute on Amazon Web Services utilizing Amazon Elastic Compute Cloud (EC2) P3 instances with GPU acceleration. Anonymized medical imagery is staged in Amazon S3 buckets, while image metadata and operational indexing reside in Amazon Relational Database Service (RDS). For clinical site integration, Aidoc supports on-premises and private-cloud VM deployments; for example, the Department of Veterans Affairs Technical Reference Model (One-VA TRM v25.4) approved the Desktop Edition of Aidoc for deployment on virtual machines within VA-controlled environments such as the VA Enterprise Cloud (VAEC). Health systems integrate the platform directly into picture archiving and communication systems (PACS) and electronic medical records (EMR) through aiOS, ensuring seamless triage alerts without disrupting baseline clinical software stacks.[CE005, CE006, CE007, CE008]

5.3 Regulatory Pathway, Data Governance, and Diligence Risks

Regulatory clearances and strict clinical oversight form the foundation of Aidoc's technical moat and risk profile. On June 25, 2026, the FDA granted Breakthrough Device Designation Q260882 for Aidoc's First Read solution, specifically designating four life-threatening findings in chest radiograph analysis. However, First Read remains strictly for investigational use and has not yet achieved 510(k) clearance or PMA market authorization. Data governance policies comply with international data transfer frameworks; Aidoc Inc. maintains active certification under the EU-U.S. Data Privacy Framework (DPF), UK Extension, and Swiss-U.S. DPF for pseudonymized scans and metadata processing. Conversely, commercial terms of use enforce stringent liability limitations: Aidoc explicitly disclaims all warranties regarding site and third-party content and caps aggregate direct damages at total fees paid during the trailing three months prior to a claim, underscoring that ultimate clinical responsibility rests with healthcare providers.[CE009, CE010, CE011, CE012]

5.4 Exhibits

6.1 Customer Segmentation and Enterprise Commercial Structure

Aidoc targets multi-facility integrated delivery networks (IDNs), academic medical centers, tertiary health systems, and large-scale physician services practices that manage heavy acute-care imaging volumes. Commercial contracting operates primarily at the enterprise level, where Chief Medical Information Officers (CMIOs), radiology department chairs, and hospital executive leadership negotiate site-wide or system-wide software subscriptions. Secondary commercial segments encompass regional community hospital clusters that access Aidoc via centralized teleradiology networks or outsourced radiology management partners, such as Radiology Partners, which represents one in ten US imaging exams. Payer and procurement dynamics demand demonstrable ROI across emergent pathways such as intracranial hemorrhage (ICH), pulmonary embolism (PE), and stroke, where clinical time savings justify recurring software allocations. However, contract sizes vary widely from five-figure single-site deployments to seven-figure IDN-wide enterprise agreements, creating distinct renewal and procurement hurdles across health system tiers. [CU001, CU002, CU003, CU004]

6.2 Adoption Trajectory and Deployment Scale Across Health Systems

The adoption trajectory for Aidoc has expanded from approximately 500 medical centers in 2021 to over 1,000 US hospital sites and nearly 2,000 hospital facilities globally by 2026. The platform's annual analytical throughput has reached approximately 60 million patient cases per year, with cumulative historical processing exceeding 120 million to 150 million patient studies. In Europe, adoption has scaled through regional networks such as Germany's Asklepios Group, which completed an enterprise rollout of the aiOS platform across 28 hospitals processing roughly 35,000 CT and X-ray examinations monthly. Cross-site utilization relies on passive background PACS integration, where automated DICOM listeners analyze studies without requiring active radiologist sign-in, maintaining engagement above 90% in health systems that enforce standardized triage protocols. Despite broad geographic reach across 30 US states and international hospital networks, public tracking metrics lack granular historical cohort data and precise annual volume disclosure per customer account. [CU005, CU006, CU007, CU008]

6.3 Named Customer Proof and Consortium Governance

Named customer proof points demonstrate deep penetration within premier US healthcare institutions and international academic centers. In August 2026, twelve leading US health systems collectively caring for nearly 20 million patients annually—including Advocate Health, Cedars-Sinai Health System, Hartford HealthCare, Houston Methodist, Mercy, Mount Sinai Health System, Northwell Health, Northwestern Medicine, Sutter Health, University of Florida Health, University Hospitals of Cleveland, and WellSpan Health—co-founded the Diagnostic AI Consortium with Aidoc to govern diagnostic AI performance, workflow integration, and post-deployment monitoring. In Europe, clinical deployments at OLVG in Amsterdam and Region Skåne in Sweden (covering 10 hospitals and over 3,000 emergency CT angiographies) demonstrate verified production use in acute trauma and stroke pathways. Furthermore, nationwide radiology physician provider Radiology Partners implemented Aidoc across its partner hospitals to support care teams and expedite emergency patient management. [CU009, CU010, CU011, CU012]

6.4 Retention Durability, Churn Risks, and Commercial Concentration

While Aidoc maintains extensive deployment breadth, commercial durability and customer concentration present critical diligence considerations. Baseline enterprise pricing starting at approximately $50,000 per site annually creates an affordability barrier for smaller community hospitals imaging under 200 acute CTs monthly, where amortized costs exceed $20 per exam. In contrast to competitors like Viz.ai and RapidAI that enjoy active clinician discourse online, independent peer-to-peer clinician sentiment regarding Aidoc on public forums remains virtually absent, suggesting purchasing decisions are predominantly administrative and executive-led. Contract renewal risk is elevated where baseline DICOM alerts push into EHR inboxes without bi-directional report write-back, as unintegrated workflows risk clinician alert fatigue. Aidoc has not publicly disclosed Net Revenue Retention (NRR), Gross Revenue Retention (GRR), logo churn, or customer account concentration, necessitating direct auditor verification of annual recurring revenue distribution and multi-year contract stability. [CU013, CU014, CU015, CU016]

6.5 Exhibits

7.1 Ranked risk posture and thesis-break conditions

The leading exposure is clinical and regulatory execution at scale. Aidoc says its platform is deployed across nearly 2,000 hospitals and supports about 60 million patient cases each year; an earlier Harvard Business School case independently described 20 algorithms in more than 900 hospitals and 17 FDA clearances in 2023. Those figures do not establish safety outcomes, but they make any model, workflow, or reporting-control failure potentially broad in reach. Public deployment figures also move from more than 900 hospitals and imaging centers to more than 1,600 medical centers and then nearly 2,000 hospitals, with different dates and denominators, so they should not be treated as a clean growth series. The investment view should break if a material patient-safety event is substantiated, a required authorization is denied or materially narrowed, or enterprise customers cannot evidence reliable clinician override, monitoring, and escalation.[CR001, CR003, CR004, CR005, CR006, CR007, CR008]

7.2 Regulatory, legal, and privacy exposure

First Read has FDA Breakthrough Device Designation, but Aidoc's syndicated announcement explicitly says the device is investigational and has not been cleared or approved. That distinction makes authorization scope and timing a gating item rather than a completed milestone. Privacy exposure is also structurally material: Aidoc's Data Privacy Framework notice says the service may process pseudonymized radiology scans, reports, metadata, usage logs, and product analytics, and it describes transfers to processors supporting cloud, identity, and data-hosting functions. The notice provides FTC oversight and complaint or arbitration paths, but it is company-issued evidence, not an independent audit of controls. The assigned evidence contains no regulator order, court docket, recall register, or independently verified incident history; absence from this bounded pool is not evidence that no such matter exists.[CR007, CR009, CR010, CR011]

7.3 Operational, clinical-quality, and security controls

Aidoc's own First Read announcement identifies errors, inconsistencies, and automation bias as known generative-reporting risks and presents clinician oversight and final approval as safeguards. That is useful risk recognition, but it does not disclose false-positive or false-negative rates, override rates, monitoring thresholds, rollback procedures, uptime, or incident-response performance. The public website terms are explicitly site terms and disclaim any guarantee that the site will be free of bugs, security breaches, or virus attacks; they cannot be used as a clinical-product service-level agreement. Separately, Aidoc's economics discussion says radiology AI vendors must articulate provider ROI and describes throughput improvement as still in its infancy. Renewal resilience therefore depends on proving both clinical reliability and realized economic value, not deployment counts alone.[CR008, CR013, CR014, CR016]

7.4 Partner, financial, and execution dependencies

The platform model introduces two dependency layers. The Harvard case says Aidoc hosted both its own and partners' algorithms, while Aidoc's current site identifies vetted third-party algorithm developers and original-equipment manufacturers as platform partners. Its privacy notice also identifies processors for cloud, identity, logs, analytics, and research data. Diligence must therefore test contractual accountability, version and validation controls, substitution rights, outage escalation, and audit coverage across both clinical and infrastructure counterparties. Aidoc's April 2026 release reports a $150 million Series E and more than $500 million of total funding, but funding raised is not cash available and discloses neither burn nor runway. Capital adequacy, customer concentration, margins, and partner concentration remain private-evidence questions rather than supportable public estimates.[CR002, CR010, CR012, CR015]

7.5 Exhibits

8.1 Recommendation and Evidence Boundary

The appropriate public-evidence recommendation is research-more, not buy or pass. Aidoc's April 2026 financing announcement supplies credible evidence of investor support and reports substantial deployment scale, but it does not provide the price or operating metrics needed to underwrite an entry. The reviewed financing materials state the amount raised and total historical funding; they do not state post-money valuation, price per share, ownership sold, liquidation preferences, revenue, margins, retention, or cash balance. Funding raised is not current cash availability, and hospital deployment is not revenue. Confidence is medium in the recommendation because the missing data are decision-critical, while confidence in any numeric valuation would be low. A price-sensitive decision therefore requires a cap table, round documents, audited financials, and customer-level economics before assigning a return case.[CV001, CV002, CV004, CV012, CV013, CV014]

8.2 Financing Context, Thesis, and Anti-Thesis

The thesis is that fresh institutional capital can fund broader indications, automated imaging draft reports, and wider aiOS deployment against an already meaningful installed base. Aidoc says the Series E was led by Growth Equity at Goldman Sachs Alternatives, with General Catalyst, SoftBank Vision Fund 2, and NVentures participating, and that the new capital will support those product and deployment priorities. The anti-thesis is that public scale claims cannot be converted into durable equity value without revenue quality, gross margin, retention, implementation cost, concentration, and cash-consumption evidence. Historical funding, including an earlier $20 million financing reported by EBN, demonstrates access to capital but not capital efficiency. The same distinction applies to the more than $500 million cumulative-funding claim: it is a financing history, not a valuation or a balance-sheet measure.[CV001, CV002, CV003, CV004, CV005, CV013]

8.3 Scenario and Comparable Framework

Public evidence supports directional scenarios but not defensible dollar ranges or revenue multiples. A bull case requires Aidoc to convert product investment and broad deployment into verified recurring growth, strong retention, software-like contribution margins, and a clean preference structure. A base case assumes continued adoption while economics and entry terms remain unresolved, which still prevents a return calculation. A bear case is triggered if commercialization fails to cover model, integration, regulatory, and support costs, or if a senior preference stack absorbs exit proceeds before common equity. The assigned comparison page is not a usable valuation benchmark: it categorizes Aidoc in a broad AI-research set and reports zero reviews. No public-company, private-round, or M&A observation in the reviewed pool supplies a comparable denominator, growth rate, margin profile, or transaction multiple.[CV003, CV004, CV010, CV011, CV012, CV015]

8.4 Liquidity, Exit Readiness, and Final Diligence Gates

EquityZen describes Aidoc exposure through funds purchasing shares from existing shareholders, not through a disclosed primary-price discovery process. It lists two possible liquidity paths for private-company investments: a company exit such as an IPO, merger, or acquisition, or an eligible Express Deal. Neither path establishes timing, availability, or proceeds for a specific Aidoc security. The data-privacy notice also identifies operational obligations relevant to downside underwriting: Aidoc says it processes pseudonymized radiology scans, reports, metadata, usage logs, and analytics, and may be liable for onward transfers under the applicable framework. Final diligence should therefore test security obligations, regulatory costs, customer concentration, cash runway, and the full preference waterfall. The thesis breaks if verified economics cannot support ongoing product and compliance investment, or if entry terms leave insufficient downside protection and target return.[CV006, CV007, CV008, CV009, CV010, CV014, CV015]

8.5 Exhibits